Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

HISTORICAL FACTS: 2 | History Defined

Pfizer Accuses Novo Nordisk Of Antitrust Violations In Metsera Takeover Battle

On Friday, Pfizer Inc. (NYSE:PFE) filed a lawsuit against Metsera, Inc. (NASDAQ:MTSR), its Board of Directors, and Novo Nordisk (NYSE:NVO) in a Delaware Court.

Benzinga

Eli Lilly Extends Lead In $150B Obesity Drug Race As Novo, Pfizer Clash — Here's How ETFs Stand To Gain

Healthcare ETFs are quietly feasting on the gains from Wall Street’s latest obsession – the $150 billion obesity-drug boom. As Eli Lilly And Co (NYSE:LLY), Novo Nordisk A/S (NYSE:NVO), and Pfizer Inc (NYSE:PFE) jostle for dominance in the fast-growing GLP-1 market, investors pile into ETFs that offer diversified and far…

Benzinga

Pfizer Blasts Novo Nordisk's $9 Billion Counteroffer For Metsera As 'Reckless'

On Thursday, Metsera Inc. (NASDAQ:MTSR) received an unsolicited acquisition proposal from Novo Nordisk A/S (NYSE:NVO).

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Options Corner: A Reliable Quant Signal Just Flashed Again For Pharma Giant Novo Nordisk

At first glance, Novo Nordisk (NYSE:NVO) doesn't appear at all enticing. Down roughly 11% in the trailing month, NVO stock has been a victim of broader market pressure. But it's also the red ink that makes the pharmaceutical giant an enticing opportunity for options traders.

Benzinga

Trump-Induced Volatility Aside, Novo Trades Cheap While Patents Protect Its Profits Until 2032

Novo Nordisk A/S (NASDAQ:NVO) is back in the headlines, and not just for its blockbuster weight-loss drug, Ozempic. President Donald Trump recently suggested a dramatic price cut for the drug, sparking some short-term market jitters. But underneath the noise, the stock is cheap at a 14 P/E, and its core…

Benzinga

Novo Nordisk Stock Is Falling Friday: What's Driving The Action?

Shares of Danish pharmaceutical giant Novo Nordisk A/S (NYSE:NVO) are trading lower Friday morning, continuing an after-hours slide that began Thursday. The decline was sparked by comments from President Donald Trump, who signaled his intent to make popular weight-loss drugs “a lot lower” in price.

Benzinga

Novo Vs. Lilly Vs. Pfizer: Who Wins If Trump Slashes The Price Of Weight Loss Drugs?

President Donald Trump just dropped a political bomb into one of Wall Street's hottest trades. His promise to cut the cost of Novo Nordisk A/S (NYSE:NVO) blockbuster drug Ozempic from around $1,300 to $150 isn't just about affordability—it's about shaking the foundations of the GLP-1 gold rush that's reshaped healthcare…

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Novo Nordisk’s Akero Therapeutics Buy Targets Eli Lilly’s Lead

Novo Nordisk’s $4.7B Akero deal boosts its metabolic health pipeline, targeting Eli Lilly’s lead in obesity and liver disease treatments

MarketBeat

Wegovy, Ozempic Maker Novo Nordisk Cuts Staff At Key US Production Sites

Novo Nordisk A/S (NYSE:NVO) has reportedly laid off dozens of employees at its largest U.S. manufacturing site in North Carolina, part of a global restructuring effort under new CEO Mike Doustdar.

Benzinga

Novo Nordisk Poised For UNH-Style Comeback: New Data & AI Boost Signal Reversal

Novo Nordisk A/S (NYSE:NVO) looks ready to shake off its slump. With weight-loss pills showing blockbuster results, Ozempic proving heart-healthy benefits, and analysts flipping bullish, the stock is starting to resemble UnitedHealth Group Inc.'s (NYSE:UNH) rebound playbook.

Benzinga

Novo Nordisk's Wegovy Outperforms Eli Lilly's Tirzepatide In Reducing Risk Of Heart Attack, Stroke, And Death: Study

Novo Nordisk A/S (NYSE:NVO) presented data from the STEER real-world study of evidence gathered from actual patient experiences at the European Society of Cardiology (ESC) Congress 2025.

Benzinga

Wegovy's Next Step: Novo Nordisk Eyes Approval for Higher-Dose Treatment

Novo Nordisk A/S (NYSE:NVO) reportedly said on Tuesday that it intends to seek US regulatory approval for a high-dose version of its weight-loss injection Wegovy (semaglutide), another effort to counter Eli Lilly and Co. (NYSE:LLY).

Benzinga

What's Going On With Novo Nordisk Shares Monday?

Novo Nordisk A/S (NYSE:NVO) shares are trading higher Monday after the company announced European Union approval for oral semaglutide to reduce cardiovascular death, heart attack and stroke.

Benzinga

Here's Novo Nordisk's First Oral Obesity Drug In Europe With Proven Heart Health Impact

On Monday, the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) approved an update to Novo Nordisk A/S‘ (NYSE:NVO) Rybelsus (oral semaglutide) label to reflect the cardiovascular benefits seen in the SOUL trial.

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Wegovy And Zepbound Cost Effective But They Could Break Drug Budgets

The Institute for Clinical and Economic Review (ICER) on Tuesday released a Draft Evidence Report assessing the comparative clinical effectiveness and value of Novo Nordisk A/S’ (NYSE:NVO) semaglutide (Wegovy) and Eli Lilly and Co.’s (NYSE:LLY) tirzepatide (Zepbound) for obesity management.

Benzinga

Ozempic Is The New Botox And Big Pharma Is Printing Billions

Ozempic and Zepbound have morphed from diabetes treatment into a cultural phenomenon, helping Novo Nordisk A/S (NYSE:NVO) and Eli Lilly And Co (NYSE:LLY) achieve a combined market cap topping $900 billion. Celebrities flaunt it, Silicon Valley elites swear by it, and analysts predict the GLP-1 market could surpass $150 billion…

Benzinga

After Copycat Boom, China's Drugmakers Target Global Generics

China-based drugmakers that once fueled a surge of copycat weight-loss treatments in the U.S. are now pivoting to generics of Novo Nordisk‘s (NYSE:NVO) Wegovy and Eli Lilly's (NYSE:LLY) Zepbound as regulators tighten rules on compounded medicines.

Benzinga

Marjorie Taylor Greene Hits Homerun Again, Buys Alphabet Stock 5 Days Before Favorable Antitrust Ruling: Here Are Some Other New Trades

Rep. Marjorie Taylor Greene (R-Ga.) purchased shares in Google’s parent company, Alphabet Inc. Class C, just five days before a significant court ruling that caused the company’s stock to surge. The trade was part of a larger buying spree on Aug. 28, 2025, where the congresswoman invested in over a…

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Novo Nordisk's Wegovy Outshines Eli Lilly's Tirzepatide In Reducing Risk Of Heart Attack, Stroke And Death

Novo Nordisk A/S (NYSE:NVO) on Sunday presented data from the STEER real-world study of evidence gathered from actual patient experiences at the European Society of Cardiology (ESC) Congress 2025.

Barchart

3 Bear Put Spread Trade Ideas For This Tuesday

A bear put spread is a vertical spread that aims to profit from a stock declining in price. It has a bearish directional bias as hinted in the name. Unlike the bear call spread, it suffers from time decay so traders need to be correct on the direction of the…

Benzinga

FDA Flags Alarming Contamination At Novo Nordisk Indiana Plant, Including Cat Hair, Bacteria, And Foreign Particles

The U.S. Food and Drug Administration (FDA) has identified repeated quality control failures, including foreign particle contamination, inadequate investigations, and insufficient corrective actions at the Novo Nordisk A/S (NYSE:NVO) operated facility in Bloomington, Indiana.

Benzinga

Options Corner: Embattled Drug Maker Novo Nordisk May Offer Speculators A Quick Profit-Scalping Opportunity

From the doldrums of the COVID-19 crisis to the early summer of 2024, few major pharmaceutical companies enjoyed as much market success as Novo Nordisk (NYSE:NVO). Much of the success was tied into the company's weight-loss drugs Wegovy and Ozempic. However, competition in the space has intensified, particularly from Eli…

Benzinga

Novo Nordisk Freezes Hiring As Wegovy Faces Copycats

Novo Nordisk A/S (NYSE:NVO) has reportedly imposed a global hiring freeze for nonessential roles, as the drugmaker faces rising competition from copycat versions of Wegovy and intensifying rivalry with Eli Lilly and Co (NYSE:LLY).

Benzinga

UnitedHealth Vs. Novo Nordisk: Which Healthcare Giant Fits Your Portfolio?

Two healthcare giants, UnitedHealth Group Inc (NYSE:UNH) and Novo Nordisk A/S (NYSE:NVO), are duking it out in very different ways for investors' attention. Both stocks have faced heavy losses this year—UNH down 38.85% YTD, NVO down 38.59%. Yet, their underlying strategies couldn't be more distinct.

Barchart

Should You Buy the Pop in Novo Nordisk Stock?

Novo Nordisk stock rallies as the Danish pharma giant makes two big announcements. TD Cowen analysts recommend buying NVO shares on the year-to-date weakness.

1 2 3 4 5

People

Marjorie Taylor Greene

3,091 stories

Mike Doustdar

23 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.